Roche still determined to go for Genentech
Roche, the Swiss pharmaceutical giant, reiterated its intention yesterday to take over the part of Genentech that it does not yet own, despite the perilous state of Europe’s debt markets. But the chances of it being able to finance the deal through the syndicated loan market are remote with banks now extremely reluctant to take on big distribution risks.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts